CMV-associated Immunomodulation in Renal Transplant Patients

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a virus called cytomegalovirus (CMV) affects the immune system of kidney transplant patients. Researchers want to understand if having CMV in the body makes it harder for these patients to fight off other infections after their transplant. By looking at how CMV interacts with the immune system, the team aims to improve the care of kidney transplant recipients.

To participate in this study, you need to be over 18 years old and either be waiting for a kidney transplant from a living donor or already have had a kidney transplant and currently have CMV in your blood. It's important to note that individuals with certain active infections or those under legal protection cannot take part. If you join the trial, you can expect to undergo tests that will help the researchers learn more about your immune response and how CMV might influence it. This study is currently not recruiting participants, but it aims to gather important information that could benefit future kidney transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. st cohort :
• • Age \> 18 years
• • patients with end-stage renal failure programmed for kidney transplantation with a live donor
• 2. nd cohort :
• • Age \> 18 years
• • kidney transplant recipient with CMV viremia
• Exclusion Criteria:
• • - Patients under guardianship, curatorship, legal protection.
• For patients with end-stage renal failure scheduled to receive a kidney transplant from a living donor :
• • Patients with an active viral (other than CMV), bacterial or fungal infection at the time of inclusion
• • patients receiving a desensitization protocol (ABO or anti-HLA)